| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obsessive-Compulsive Disorder | 234 | 2025 | 795 | 23.760 |
Why?
|
| Deep Brain Stimulation | 57 | 2025 | 411 | 8.960 |
Why?
|
| Tourette Syndrome | 35 | 2025 | 155 | 3.180 |
Why?
|
| Psychiatric Status Rating Scales | 59 | 2025 | 816 | 2.840 |
Why?
|
| Anxiety Disorders | 38 | 2024 | 688 | 2.660 |
Why?
|
| Tic Disorders | 17 | 2025 | 78 | 2.250 |
Why?
|
| Brain | 33 | 2025 | 2994 | 2.180 |
Why?
|
| Psychometrics | 32 | 2025 | 673 | 2.170 |
Why?
|
| Mental Disorders | 21 | 2024 | 827 | 2.130 |
Why?
|
| Transcranial Magnetic Stimulation | 10 | 2023 | 71 | 1.840 |
Why?
|
| Emotions | 16 | 2023 | 360 | 1.830 |
Why?
|
| Internal Capsule | 10 | 2023 | 49 | 1.770 |
Why?
|
| Humans | 335 | 2025 | 124906 | 1.740 |
Why?
|
| Surveys and Questionnaires | 34 | 2024 | 3729 | 1.720 |
Why?
|
| Adolescent | 118 | 2025 | 19343 | 1.680 |
Why?
|
| Anxiety | 32 | 2025 | 964 | 1.680 |
Why?
|
| Streptococcal Infections | 10 | 2024 | 243 | 1.660 |
Why?
|
| Severity of Illness Index | 54 | 2025 | 2902 | 1.620 |
Why?
|
| Ondansetron | 2 | 2025 | 10 | 1.570 |
Why?
|
| Parents | 20 | 2024 | 1023 | 1.530 |
Why?
|
| Implosive Therapy | 7 | 2025 | 89 | 1.520 |
Why?
|
| Adult | 161 | 2025 | 29576 | 1.510 |
Why?
|
| Treatment Outcome | 77 | 2025 | 12405 | 1.480 |
Why?
|
| Cerebral Cortex | 8 | 2024 | 452 | 1.450 |
Why?
|
| Connectome | 3 | 2023 | 99 | 1.430 |
Why?
|
| Prefrontal Cortex | 13 | 2024 | 184 | 1.390 |
Why?
|
| Male | 195 | 2025 | 61395 | 1.340 |
Why?
|
| Antipsychotic Agents | 10 | 2024 | 369 | 1.290 |
Why?
|
| Depression | 22 | 2025 | 1236 | 1.280 |
Why?
|
| Female | 194 | 2025 | 66678 | 1.260 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 10 | 2022 | 209 | 1.230 |
Why?
|
| Depressive Disorder, Major | 13 | 2024 | 399 | 1.210 |
Why?
|
| Nerve Net | 6 | 2021 | 241 | 1.130 |
Why?
|
| Child | 95 | 2025 | 24410 | 1.130 |
Why?
|
| Septal Nuclei | 2 | 2023 | 14 | 1.040 |
Why?
|
| Personality Inventory | 23 | 2010 | 168 | 1.000 |
Why?
|
| Psychiatry | 2 | 2023 | 263 | 0.970 |
Why?
|
| Middle Aged | 88 | 2025 | 26879 | 0.960 |
Why?
|
| Serotonin 5-HT3 Receptor Antagonists | 1 | 2025 | 3 | 0.960 |
Why?
|
| Attention | 4 | 2019 | 202 | 0.940 |
Why?
|
| Fluoxetine | 11 | 2009 | 43 | 0.920 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 5 | 2024 | 117 | 0.920 |
Why?
|
| Electroconvulsive Therapy | 4 | 2016 | 68 | 0.920 |
Why?
|
| Streptococcus pyogenes | 5 | 2011 | 76 | 0.910 |
Why?
|
| Interoception | 3 | 2018 | 7 | 0.910 |
Why?
|
| Subthalamic Nucleus | 3 | 2021 | 60 | 0.900 |
Why?
|
| Serotonin Antagonists | 9 | 2018 | 24 | 0.900 |
Why?
|
| Depressive Disorder | 19 | 2024 | 454 | 0.890 |
Why?
|
| Antidepressive Agents | 14 | 2024 | 290 | 0.870 |
Why?
|
| Young Adult | 29 | 2025 | 9051 | 0.840 |
Why?
|
| Cognition | 9 | 2022 | 731 | 0.840 |
Why?
|
| Comorbidity | 26 | 2024 | 1532 | 0.840 |
Why?
|
| Affect | 8 | 2017 | 158 | 0.840 |
Why?
|
| Reproducibility of Results | 27 | 2025 | 2881 | 0.790 |
Why?
|
| Brain Mapping | 11 | 2023 | 397 | 0.790 |
Why?
|
| Suicidal Ideation | 4 | 2024 | 219 | 0.790 |
Why?
|
| Tics | 4 | 2010 | 49 | 0.770 |
Why?
|
| Family | 11 | 2023 | 566 | 0.770 |
Why?
|
| Emergency Shelter | 2 | 2019 | 8 | 0.750 |
Why?
|
| Ventral Striatum | 5 | 2024 | 34 | 0.750 |
Why?
|
| Nucleus Accumbens | 5 | 2010 | 54 | 0.740 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2025 | 3572 | 0.730 |
Why?
|
| Psychosurgery | 3 | 2023 | 27 | 0.690 |
Why?
|
| Double-Blind Method | 31 | 2025 | 1645 | 0.680 |
Why?
|
| Autistic Disorder | 8 | 2025 | 348 | 0.680 |
Why?
|
| Combined Modality Therapy | 21 | 2024 | 1240 | 0.680 |
Why?
|
| Autoimmune Diseases | 4 | 2024 | 251 | 0.680 |
Why?
|
| Cycloserine | 4 | 2019 | 23 | 0.670 |
Why?
|
| Behavior Therapy | 12 | 2020 | 253 | 0.660 |
Why?
|
| Fluvoxamine | 22 | 2009 | 25 | 0.650 |
Why?
|
| Autism Spectrum Disorder | 6 | 2025 | 390 | 0.620 |
Why?
|
| Factor Analysis, Statistical | 13 | 2025 | 238 | 0.610 |
Why?
|
| Suicide | 5 | 2023 | 174 | 0.600 |
Why?
|
| Serotonin | 18 | 1997 | 219 | 0.590 |
Why?
|
| Anhedonia | 4 | 2024 | 29 | 0.590 |
Why?
|
| Parkinson Disease | 6 | 2023 | 693 | 0.590 |
Why?
|
| Civil Defense | 1 | 2018 | 8 | 0.590 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2018 | 20 | 0.580 |
Why?
|
| Quality of Life | 13 | 2023 | 1944 | 0.570 |
Why?
|
| Family Therapy | 3 | 2007 | 34 | 0.570 |
Why?
|
| Citalopram | 3 | 2005 | 30 | 0.540 |
Why?
|
| Gyrus Cinguli | 5 | 2024 | 116 | 0.530 |
Why?
|
| Olfactory Perception | 1 | 2017 | 27 | 0.530 |
Why?
|
| Disasters | 1 | 2018 | 102 | 0.530 |
Why?
|
| Thalamus | 5 | 2023 | 83 | 0.510 |
Why?
|
| Interview, Psychological | 2 | 2013 | 97 | 0.500 |
Why?
|
| Stress Disorders, Post-Traumatic | 6 | 2024 | 628 | 0.490 |
Why?
|
| Survivors | 1 | 2018 | 336 | 0.490 |
Why?
|
| Signal Detection, Psychological | 2 | 2014 | 10 | 0.480 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 2020 | 225 | 0.470 |
Why?
|
| Mental Health Services | 1 | 2018 | 256 | 0.470 |
Why?
|
| Hearing Disorders | 3 | 2023 | 27 | 0.470 |
Why?
|
| Trichotillomania | 2 | 2014 | 34 | 0.470 |
Why?
|
| Narcotic Antagonists | 3 | 2020 | 109 | 0.470 |
Why?
|
| Visual Cortex | 1 | 2016 | 126 | 0.460 |
Why?
|
| Cyclonic Storms | 3 | 2022 | 76 | 0.460 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2014 | 17 | 0.460 |
Why?
|
| Sertraline | 9 | 2015 | 44 | 0.450 |
Why?
|
| Neurosciences | 2 | 2019 | 50 | 0.450 |
Why?
|
| Awareness | 4 | 2017 | 79 | 0.440 |
Why?
|
| Adaptation, Psychological | 5 | 2023 | 450 | 0.430 |
Why?
|
| Oximes | 9 | 1991 | 55 | 0.430 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 3 | 2008 | 44 | 0.420 |
Why?
|
| Radiosurgery | 3 | 2023 | 111 | 0.420 |
Why?
|
| Neuropsychological Tests | 9 | 2017 | 925 | 0.420 |
Why?
|
| Artifacts | 3 | 2023 | 109 | 0.420 |
Why?
|
| Fear | 6 | 2015 | 200 | 0.420 |
Why?
|
| Reward | 2 | 2024 | 111 | 0.420 |
Why?
|
| Age Factors | 13 | 2019 | 2823 | 0.410 |
Why?
|
| Models, Neurological | 1 | 2014 | 216 | 0.410 |
Why?
|
| Neurosurgery | 3 | 2023 | 74 | 0.410 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 56 | 0.400 |
Why?
|
| Drug Discovery | 4 | 2010 | 171 | 0.390 |
Why?
|
| Telemedicine | 3 | 2023 | 435 | 0.390 |
Why?
|
| Habenula | 3 | 2018 | 41 | 0.390 |
Why?
|
| Functional Laterality | 3 | 2010 | 183 | 0.390 |
Why?
|
| Panic | 9 | 2006 | 18 | 0.380 |
Why?
|
| Electromagnetic Fields | 3 | 2022 | 26 | 0.370 |
Why?
|
| Self Report | 6 | 2024 | 518 | 0.370 |
Why?
|
| Device Approval | 1 | 2011 | 12 | 0.370 |
Why?
|
| Attitude of Health Personnel | 3 | 2024 | 664 | 0.370 |
Why?
|
| Anger | 3 | 2022 | 30 | 0.370 |
Why?
|
| Mental Health | 4 | 2023 | 344 | 0.360 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2023 | 236 | 0.350 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2023 | 258 | 0.340 |
Why?
|
| Aged | 29 | 2022 | 19835 | 0.330 |
Why?
|
| Implantable Neurostimulators | 2 | 2020 | 18 | 0.330 |
Why?
|
| Attitude | 3 | 2020 | 116 | 0.330 |
Why?
|
| Clinical Trials as Topic | 14 | 2020 | 1093 | 0.330 |
Why?
|
| Health Status | 2 | 2009 | 376 | 0.320 |
Why?
|
| Smiling | 2 | 2010 | 4 | 0.320 |
Why?
|
| Stereotaxic Techniques | 2 | 2024 | 70 | 0.320 |
Why?
|
| Child Behavior Disorders | 6 | 2009 | 67 | 0.320 |
Why?
|
| Neurosurgical Procedures | 3 | 2023 | 304 | 0.310 |
Why?
|
| Biomedical Research | 2 | 2019 | 519 | 0.310 |
Why?
|
| Anti-Anxiety Agents | 3 | 2004 | 74 | 0.310 |
Why?
|
| Suicide, Attempted | 4 | 2024 | 131 | 0.310 |
Why?
|
| Personality Assessment | 7 | 2008 | 105 | 0.310 |
Why?
|
| Mood Disorders | 3 | 2023 | 123 | 0.300 |
Why?
|
| Internal-External Control | 10 | 2019 | 75 | 0.300 |
Why?
|
| Schizophrenia | 2 | 2008 | 301 | 0.300 |
Why?
|
| Family Health | 4 | 2019 | 259 | 0.290 |
Why?
|
| Electric Stimulation Therapy | 2 | 2006 | 103 | 0.290 |
Why?
|
| Psychology, Child | 2 | 2008 | 44 | 0.280 |
Why?
|
| Benzodiazepines | 3 | 2004 | 100 | 0.280 |
Why?
|
| Neural Pathways | 4 | 2021 | 266 | 0.280 |
Why?
|
| Politics | 2 | 2018 | 59 | 0.280 |
Why?
|
| Analysis of Variance | 9 | 2014 | 1017 | 0.280 |
Why?
|
| Reversal Learning | 2 | 2018 | 7 | 0.280 |
Why?
|
| Compulsive Behavior | 5 | 2011 | 41 | 0.280 |
Why?
|
| Adolescent Behavior | 3 | 2019 | 168 | 0.280 |
Why?
|
| Neuroimaging | 4 | 2023 | 340 | 0.280 |
Why?
|
| Electroencephalography | 4 | 2024 | 865 | 0.280 |
Why?
|
| Anorexia Nervosa | 2 | 2018 | 24 | 0.280 |
Why?
|
| Brain Diseases | 2 | 2018 | 299 | 0.280 |
Why?
|
| Psychotic Disorders | 1 | 2008 | 136 | 0.270 |
Why?
|
| Psychology, Adolescent | 1 | 2006 | 32 | 0.270 |
Why?
|
| Behavior | 2 | 2006 | 74 | 0.270 |
Why?
|
| Central Nervous System Bacterial Infections | 1 | 2006 | 5 | 0.270 |
Why?
|
| Tryptophan | 12 | 1997 | 90 | 0.270 |
Why?
|
| Drug Monitoring | 1 | 2008 | 172 | 0.270 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 149 | 0.260 |
Why?
|
| Essential Tremor | 2 | 2023 | 89 | 0.250 |
Why?
|
| Autoantibodies | 2 | 2006 | 434 | 0.250 |
Why?
|
| Students | 2 | 2000 | 250 | 0.250 |
Why?
|
| Imagination | 2 | 2016 | 17 | 0.250 |
Why?
|
| United States | 15 | 2025 | 10909 | 0.240 |
Why?
|
| Clomipramine | 12 | 2009 | 15 | 0.240 |
Why?
|
| Sleep Wake Disorders | 1 | 2007 | 167 | 0.240 |
Why?
|
| Caudate Nucleus | 2 | 2017 | 35 | 0.240 |
Why?
|
| Child, Preschool | 14 | 2023 | 14019 | 0.240 |
Why?
|
| Limbic System | 3 | 2013 | 22 | 0.230 |
Why?
|
| Drug Resistance | 4 | 2013 | 257 | 0.230 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2018 | 13 | 0.230 |
Why?
|
| Prostheses and Implants | 1 | 2006 | 152 | 0.230 |
Why?
|
| Auditory Cortex | 1 | 2024 | 29 | 0.230 |
Why?
|
| Acoustic Stimulation | 1 | 2024 | 85 | 0.230 |
Why?
|
| Intraoperative Period | 1 | 2004 | 74 | 0.230 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2023 | 127 | 0.220 |
Why?
|
| B-Lymphocytes | 3 | 2002 | 533 | 0.220 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2023 | 23 | 0.220 |
Why?
|
| Data Compression | 1 | 2023 | 12 | 0.210 |
Why?
|
| Treatment Failure | 4 | 2008 | 337 | 0.210 |
Why?
|
| Electrodes, Implanted | 5 | 2024 | 169 | 0.210 |
Why?
|
| Rheumatic Fever | 3 | 2002 | 18 | 0.210 |
Why?
|
| Parturition | 1 | 2024 | 63 | 0.210 |
Why?
|
| Dopamine | 5 | 1993 | 283 | 0.210 |
Why?
|
| Patient Education as Topic | 3 | 2021 | 442 | 0.210 |
Why?
|
| United States Food and Drug Administration | 5 | 2011 | 149 | 0.210 |
Why?
|
| China | 5 | 2023 | 245 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2013 | 1692 | 0.200 |
Why?
|
| Attitude to Health | 5 | 2009 | 256 | 0.200 |
Why?
|
| Hyperacusis | 1 | 2022 | 4 | 0.200 |
Why?
|
| Behavioral Symptoms | 2 | 2019 | 25 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6588 | 0.200 |
Why?
|
| Drug Administration Schedule | 8 | 2006 | 727 | 0.200 |
Why?
|
| Motivation | 4 | 2023 | 318 | 0.200 |
Why?
|
| Arousal | 7 | 2017 | 81 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 580 | 0.200 |
Why?
|
| Psychotherapy | 2 | 2024 | 230 | 0.200 |
Why?
|
| Self-Injurious Behavior | 2 | 2002 | 63 | 0.190 |
Why?
|
| Placebos | 9 | 2007 | 241 | 0.190 |
Why?
|
| Antibodies, Bacterial | 1 | 2004 | 388 | 0.190 |
Why?
|
| Fructose | 1 | 2002 | 62 | 0.190 |
Why?
|
| Prader-Willi Syndrome | 1 | 2002 | 67 | 0.190 |
Why?
|
| Perception | 2 | 2021 | 220 | 0.190 |
Why?
|
| United Kingdom | 2 | 2020 | 190 | 0.180 |
Why?
|
| Critical Care | 1 | 2007 | 656 | 0.180 |
Why?
|
| Angelman Syndrome | 1 | 2022 | 68 | 0.180 |
Why?
|
| Dystonia | 1 | 2023 | 171 | 0.180 |
Why?
|
| Electrophysiology | 1 | 2021 | 270 | 0.180 |
Why?
|
| Electrodes | 4 | 2024 | 98 | 0.180 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 24 | 0.180 |
Why?
|
| Corpus Striatum | 4 | 2008 | 91 | 0.180 |
Why?
|
| Retrospective Studies | 9 | 2024 | 16345 | 0.180 |
Why?
|
| Drug Interactions | 2 | 2018 | 253 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 123 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2002 | 160 | 0.170 |
Why?
|
| Food | 2 | 2018 | 125 | 0.170 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 456 | 0.170 |
Why?
|
| Piperazines | 6 | 1999 | 238 | 0.170 |
Why?
|
| Conduct Disorder | 1 | 2020 | 32 | 0.170 |
Why?
|
| Cytokines | 1 | 2006 | 1290 | 0.170 |
Why?
|
| Follow-Up Studies | 10 | 2016 | 5165 | 0.170 |
Why?
|
| Serotonin Receptor Agonists | 3 | 1999 | 23 | 0.170 |
Why?
|
| Pyrrolidines | 1 | 2020 | 36 | 0.170 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 23 | 0.170 |
Why?
|
| Faculty | 1 | 2021 | 102 | 0.170 |
Why?
|
| Adrenergic Uptake Inhibitors | 3 | 2009 | 27 | 0.170 |
Why?
|
| Pandemics | 3 | 2022 | 1108 | 0.170 |
Why?
|
| Sensation | 2 | 2017 | 58 | 0.170 |
Why?
|
| Photic Stimulation | 2 | 2015 | 223 | 0.160 |
Why?
|
| White Matter | 1 | 2022 | 177 | 0.160 |
Why?
|
| Drug Therapy, Combination | 12 | 2013 | 1165 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 4 | 2025 | 509 | 0.160 |
Why?
|
| Health Personnel | 1 | 2024 | 505 | 0.160 |
Why?
|
| Benzamides | 1 | 2020 | 108 | 0.160 |
Why?
|
| Chorea | 4 | 2006 | 39 | 0.160 |
Why?
|
| Residential Treatment | 1 | 2019 | 11 | 0.160 |
Why?
|
| Treatment Refusal | 1 | 2020 | 77 | 0.160 |
Why?
|
| Epilepsy | 2 | 2024 | 871 | 0.160 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2009 | 141 | 0.160 |
Why?
|
| Observer Variation | 4 | 2007 | 297 | 0.160 |
Why?
|
| Evoked Potentials, Motor | 1 | 1999 | 33 | 0.160 |
Why?
|
| Body Image | 2 | 1997 | 38 | 0.160 |
Why?
|
| Single-Blind Method | 4 | 2010 | 237 | 0.150 |
Why?
|
| Touch Perception | 1 | 2018 | 17 | 0.150 |
Why?
|
| Neural Prostheses | 1 | 2018 | 4 | 0.150 |
Why?
|
| Cues | 1 | 2018 | 92 | 0.150 |
Why?
|
| Brain-Computer Interfaces | 1 | 2018 | 13 | 0.150 |
Why?
|
| Prognosis | 7 | 2015 | 4631 | 0.150 |
Why?
|
| Data Mining | 1 | 2018 | 53 | 0.150 |
Why?
|
| Bioethics | 1 | 2019 | 69 | 0.150 |
Why?
|
| Patient Preference | 1 | 2019 | 119 | 0.150 |
Why?
|
| Habits | 1 | 2018 | 26 | 0.150 |
Why?
|
| Case-Control Studies | 7 | 2018 | 3289 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2019 | 473 | 0.140 |
Why?
|
| Research Subjects | 1 | 2018 | 54 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2019 | 161 | 0.140 |
Why?
|
| Risk Factors | 9 | 2019 | 10285 | 0.140 |
Why?
|
| Device Removal | 1 | 2019 | 221 | 0.140 |
Why?
|
| Psychotropic Drugs | 4 | 2022 | 122 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2020 | 4808 | 0.140 |
Why?
|
| Transportation of Patients | 1 | 2018 | 58 | 0.140 |
Why?
|
| Checklist | 2 | 2022 | 86 | 0.140 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2017 | 19 | 0.140 |
Why?
|
| N-Methylaspartate | 1 | 2017 | 28 | 0.140 |
Why?
|
| Putamen | 1 | 2016 | 19 | 0.130 |
Why?
|
| Obsessive Behavior | 3 | 2011 | 20 | 0.130 |
Why?
|
| Phobic Disorders | 1 | 1997 | 43 | 0.130 |
Why?
|
| International Cooperation | 2 | 2015 | 157 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2018 | 176 | 0.130 |
Why?
|
| Computer Simulation | 3 | 2025 | 646 | 0.130 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 3 | 1992 | 4 | 0.130 |
Why?
|
| Occipital Lobe | 1 | 2016 | 32 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2019 | 371 | 0.130 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 502 | 0.130 |
Why?
|
| Students, Medical | 1 | 2021 | 357 | 0.130 |
Why?
|
| Logistic Models | 5 | 2018 | 1812 | 0.130 |
Why?
|
| Avoidance Learning | 2 | 2015 | 58 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 415 | 0.130 |
Why?
|
| Buspirone | 5 | 2004 | 12 | 0.120 |
Why?
|
| Conditioning, Classical | 1 | 2015 | 54 | 0.120 |
Why?
|
| Pilot Projects | 5 | 2013 | 1397 | 0.120 |
Why?
|
| Amygdala | 1 | 2015 | 76 | 0.120 |
Why?
|
| Myelin Sheath | 1 | 2016 | 118 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2018 | 385 | 0.120 |
Why?
|
| Texas | 2 | 2024 | 3586 | 0.120 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2015 | 94 | 0.120 |
Why?
|
| Compulsive Personality Disorder | 2 | 2008 | 14 | 0.120 |
Why?
|
| Psychophysics | 1 | 2014 | 15 | 0.110 |
Why?
|
| Chronic Disease | 4 | 2008 | 1190 | 0.110 |
Why?
|
| Recurrence | 4 | 2011 | 1421 | 0.110 |
Why?
|
| Isoxazoles | 2 | 2013 | 24 | 0.110 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2010 | 39 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2010 | 6155 | 0.110 |
Why?
|
| Time Factors | 7 | 2020 | 6320 | 0.110 |
Why?
|
| Reaction Time | 1 | 2014 | 175 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 850 | 0.110 |
Why?
|
| Caregivers | 4 | 2022 | 576 | 0.110 |
Why?
|
| Insanity Defense | 1 | 1993 | 3 | 0.100 |
Why?
|
| Parent-Child Relations | 2 | 2019 | 247 | 0.100 |
Why?
|
| Prevalence | 4 | 2007 | 2448 | 0.100 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 140 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2020 | 1000 | 0.100 |
Why?
|
| Expert Testimony | 1 | 1993 | 37 | 0.100 |
Why?
|
| History, 19th Century | 1 | 2013 | 116 | 0.100 |
Why?
|
| Sex Factors | 7 | 2019 | 1287 | 0.100 |
Why?
|
| Syndrome | 2 | 2022 | 1120 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2018 | 641 | 0.100 |
Why?
|
| 1-Naphthylamine | 5 | 1997 | 6 | 0.100 |
Why?
|
| Ketamine | 1 | 2015 | 216 | 0.090 |
Why?
|
| Biomarkers | 6 | 2024 | 3069 | 0.090 |
Why?
|
| Dichotic Listening Tests | 1 | 1991 | 5 | 0.090 |
Why?
|
| Yohimbine | 4 | 1995 | 18 | 0.090 |
Why?
|
| Longitudinal Studies | 5 | 2020 | 1329 | 0.090 |
Why?
|
| Bipolar Disorder | 2 | 2015 | 340 | 0.090 |
Why?
|
| Family Relations | 2 | 2023 | 68 | 0.090 |
Why?
|
| Statistics as Topic | 3 | 2007 | 256 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2013 | 383 | 0.090 |
Why?
|
| Animals | 11 | 2021 | 34057 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2013 | 371 | 0.090 |
Why?
|
| Extinction, Psychological | 2 | 2025 | 23 | 0.090 |
Why?
|
| Oxygen | 1 | 2014 | 553 | 0.090 |
Why?
|
| Child Behavior | 1 | 2012 | 230 | 0.090 |
Why?
|
| Judgment | 1 | 2010 | 36 | 0.090 |
Why?
|
| Aggression | 3 | 2007 | 223 | 0.090 |
Why?
|
| Laughter | 1 | 2010 | 10 | 0.090 |
Why?
|
| Patient Selection | 1 | 2014 | 696 | 0.080 |
Why?
|
| Bacterial Proteins | 2 | 2006 | 889 | 0.080 |
Why?
|
| Risperidone | 2 | 2009 | 59 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 133 | 0.080 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2001 | 36 | 0.080 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.080 |
Why?
|
| Neurosecretory Systems | 1 | 1989 | 23 | 0.080 |
Why?
|
| Stress, Psychological | 4 | 2021 | 559 | 0.080 |
Why?
|
| Therapies, Investigational | 1 | 2008 | 12 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2010 | 375 | 0.080 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2008 | 19 | 0.080 |
Why?
|
| Drug Industry | 1 | 2008 | 46 | 0.080 |
Why?
|
| Basal Ganglia | 3 | 2002 | 56 | 0.070 |
Why?
|
| Receptors, Serotonin | 5 | 1993 | 42 | 0.070 |
Why?
|
| Haloperidol | 3 | 1999 | 23 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 12 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2154 | 0.070 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2008 | 6 | 0.070 |
Why?
|
| Defense Mechanisms | 3 | 2019 | 12 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2020 | 286 | 0.070 |
Why?
|
| Age Distribution | 2 | 2007 | 415 | 0.070 |
Why?
|
| Neurobiology | 1 | 2008 | 25 | 0.070 |
Why?
|
| Panic Disorder | 3 | 2008 | 46 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2006 | 1885 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2008 | 116 | 0.070 |
Why?
|
| Cerebellum | 1 | 1991 | 415 | 0.070 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2008 | 55 | 0.070 |
Why?
|
| Desensitization, Psychologic | 1 | 2007 | 6 | 0.070 |
Why?
|
| Safety | 1 | 2008 | 217 | 0.070 |
Why?
|
| Feeding and Eating Disorders of Childhood | 1 | 2007 | 15 | 0.070 |
Why?
|
| Disease Progression | 1 | 2013 | 2060 | 0.070 |
Why?
|
| Retreatment | 1 | 2007 | 89 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 303 | 0.070 |
Why?
|
| Florida | 3 | 2008 | 78 | 0.070 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2006 | 16 | 0.070 |
Why?
|
| Clonidine | 1 | 1986 | 36 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 221 | 0.060 |
Why?
|
| Education | 1 | 2007 | 109 | 0.060 |
Why?
|
| Neuroanatomy | 1 | 2006 | 11 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 249 | 0.060 |
Why?
|
| Oxytocin | 3 | 1999 | 68 | 0.060 |
Why?
|
| Dominance, Cerebral | 1 | 2006 | 56 | 0.060 |
Why?
|
| Desipramine | 3 | 1997 | 27 | 0.060 |
Why?
|
| Heart Rate | 3 | 2006 | 590 | 0.060 |
Why?
|
| Algorithms | 2 | 2023 | 1624 | 0.060 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1985 | 11 | 0.060 |
Why?
|
| Autonomic Nervous System | 1 | 2006 | 45 | 0.060 |
Why?
|
| Crime Victims | 1 | 2006 | 58 | 0.060 |
Why?
|
| Neurologic Examination | 4 | 2006 | 193 | 0.060 |
Why?
|
| Peer Group | 1 | 2006 | 118 | 0.060 |
Why?
|
| Amoxicillin | 1 | 2006 | 121 | 0.060 |
Why?
|
| Sound | 1 | 2025 | 21 | 0.060 |
Why?
|
| Spain | 1 | 2025 | 59 | 0.060 |
Why?
|
| Electric Stimulation | 1 | 2006 | 325 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2007 | 3436 | 0.060 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2024 | 53 | 0.060 |
Why?
|
| Norepinephrine | 4 | 1996 | 175 | 0.060 |
Why?
|
| Models, Psychological | 2 | 2008 | 138 | 0.060 |
Why?
|
| Universities | 2 | 2008 | 125 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 239 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2025 | 95 | 0.060 |
Why?
|
| Beta Rhythm | 1 | 2024 | 22 | 0.060 |
Why?
|
| Language | 2 | 2019 | 201 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2004 | 87 | 0.060 |
Why?
|
| Facial Expression | 1 | 2004 | 28 | 0.060 |
Why?
|
| Phantoms, Imaging | 1 | 2025 | 134 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2025 | 111 | 0.060 |
Why?
|
| Periodicity | 1 | 2024 | 55 | 0.060 |
Why?
|
| Pupil | 1 | 2024 | 71 | 0.060 |
Why?
|
| Hydroxyzine | 1 | 2004 | 2 | 0.060 |
Why?
|
| Streptolysins | 1 | 2004 | 9 | 0.060 |
Why?
|
| Histamine H1 Antagonists | 1 | 2004 | 12 | 0.060 |
Why?
|
| Deoxyribonucleases | 1 | 2004 | 27 | 0.060 |
Why?
|
| Electroshock | 1 | 2004 | 28 | 0.060 |
Why?
|
| Thinking | 2 | 2022 | 36 | 0.060 |
Why?
|
| Carbohydrates | 1 | 2004 | 34 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 2051 | 0.060 |
Why?
|
| Videotape Recording | 1 | 2004 | 57 | 0.050 |
Why?
|
| Magnetics | 1 | 2004 | 40 | 0.050 |
Why?
|
| Ambulatory Care | 5 | 2003 | 388 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2024 | 145 | 0.050 |
Why?
|
| Lithium | 3 | 1993 | 66 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2024 | 2428 | 0.050 |
Why?
|
| Neurophysiological Monitoring | 1 | 2024 | 37 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2006 | 277 | 0.050 |
Why?
|
| Vagus Nerve | 1 | 2004 | 44 | 0.050 |
Why?
|
| Computers | 1 | 2023 | 68 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2024 | 132 | 0.050 |
Why?
|
| Paroxetine | 2 | 1994 | 28 | 0.050 |
Why?
|
| Terminology as Topic | 4 | 2010 | 222 | 0.050 |
Why?
|
| Light | 1 | 2023 | 174 | 0.050 |
Why?
|
| Incidence | 3 | 2019 | 3140 | 0.050 |
Why?
|
| Psychological Tests | 2 | 2000 | 91 | 0.050 |
Why?
|
| Electromagnetic Radiation | 1 | 2022 | 4 | 0.050 |
Why?
|
| Hydrocortisone | 9 | 1999 | 217 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 134 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 305 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2024 | 213 | 0.050 |
Why?
|
| Impulsive Behavior | 1 | 2023 | 145 | 0.050 |
Why?
|
| Psychophysiology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 248 | 0.050 |
Why?
|
| Psychoneuroimmunology | 1 | 2001 | 2 | 0.050 |
Why?
|
| Dynorphins | 2 | 1999 | 9 | 0.050 |
Why?
|
| Biogenic Amines | 3 | 1999 | 19 | 0.050 |
Why?
|
| Health Surveys | 1 | 2023 | 242 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2001 | 99 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2025 | 292 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2008 | 2096 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2010 | 3449 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2010 | 1116 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 2021 | 50 | 0.040 |
Why?
|
| Methoxyhydroxyphenylglycol | 6 | 1995 | 35 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 205 | 0.040 |
Why?
|
| Functional Neuroimaging | 1 | 2020 | 30 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 325 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2025 | 933 | 0.040 |
Why?
|
| Central Nervous System Agents | 1 | 2020 | 14 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 29 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2021 | 89 | 0.040 |
Why?
|
| Research Design | 2 | 2021 | 693 | 0.040 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 1999 | 58 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 475 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 1999 | 63 | 0.040 |
Why?
|
| Behavior Observation Techniques | 1 | 2019 | 5 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1269 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 2 | 2010 | 156 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2015 | 472 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 253 | 0.040 |
Why?
|
| beta-Endorphin | 1 | 1999 | 10 | 0.040 |
Why?
|
| Differential Threshold | 1 | 1999 | 11 | 0.040 |
Why?
|
| Disease Resistance | 1 | 2019 | 23 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 307 | 0.040 |
Why?
|
| Ethics, Research | 1 | 2019 | 51 | 0.040 |
Why?
|
| Meglumine | 1 | 1999 | 14 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 1999 | 43 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 798 | 0.040 |
Why?
|
| Pindolol | 1 | 1999 | 8 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 100 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 812 | 0.040 |
Why?
|
| Problem Behavior | 1 | 2019 | 37 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 424 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 759 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2018 | 5 | 0.040 |
Why?
|
| Raphe Nuclei | 1 | 2018 | 17 | 0.040 |
Why?
|
| Clozapine | 2 | 1995 | 23 | 0.040 |
Why?
|
| Duty to Recontact | 1 | 2018 | 2 | 0.040 |
Why?
|
| Echo-Planar Imaging | 1 | 2018 | 21 | 0.040 |
Why?
|
| Locus Coeruleus | 1 | 2018 | 22 | 0.040 |
Why?
|
| Motor Cortex | 1 | 1999 | 77 | 0.040 |
Why?
|
| Somatosensory Cortex | 1 | 2018 | 53 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 431 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 110 | 0.040 |
Why?
|
| Dopaminergic Neurons | 1 | 2018 | 45 | 0.040 |
Why?
|
| Neuropeptides | 1 | 1999 | 113 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2001 | 1031 | 0.040 |
Why?
|
| Indoles | 1 | 1999 | 187 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 253 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 351 | 0.040 |
Why?
|
| Individuality | 1 | 2017 | 34 | 0.040 |
Why?
|
| Stereotyped Behavior | 2 | 1995 | 37 | 0.040 |
Why?
|
| Prolactin | 6 | 1999 | 108 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 780 | 0.030 |
Why?
|
| Age of Onset | 5 | 1999 | 590 | 0.030 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 1997 | 31 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 265 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 229 | 0.030 |
Why?
|
| Antigens | 1 | 1997 | 155 | 0.030 |
Why?
|
| Basal Ganglia Diseases | 1 | 1996 | 27 | 0.030 |
Why?
|
| Somatoform Disorders | 1 | 1997 | 46 | 0.030 |
Why?
|
| Social Behavior | 4 | 2006 | 209 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 430 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 58 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2016 | 49 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1996 | 147 | 0.030 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2015 | 11 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 2 | 2014 | 276 | 0.030 |
Why?
|
| Facial Muscles | 1 | 2015 | 33 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1995 | 48 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1999 | 779 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 2 | 1994 | 28 | 0.030 |
Why?
|
| Electromyography | 1 | 2015 | 165 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2016 | 163 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2007 | 402 | 0.030 |
Why?
|
| Hippocampus | 1 | 2020 | 825 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 497 | 0.030 |
Why?
|
| Piperidines | 2 | 1994 | 208 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1995 | 556 | 0.030 |
Why?
|
| Observation | 1 | 2014 | 42 | 0.030 |
Why?
|
| Dopamine Antagonists | 1 | 1994 | 50 | 0.030 |
Why?
|
| Paliperidone Palmitate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Clonazepam | 1 | 1993 | 5 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1179 | 0.030 |
Why?
|
| Fenfluramine | 1 | 1993 | 11 | 0.030 |
Why?
|
| Trazodone | 1 | 1993 | 6 | 0.030 |
Why?
|
| Decision Trees | 1 | 1993 | 49 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1995 | 682 | 0.030 |
Why?
|
| Phototherapy | 1 | 1993 | 34 | 0.030 |
Why?
|
| Sick Role | 1 | 1993 | 31 | 0.030 |
Why?
|
| Delusions | 1 | 1992 | 17 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 1993 | 50 | 0.030 |
Why?
|
| Liability, Legal | 1 | 1993 | 44 | 0.030 |
Why?
|
| Relaxation Therapy | 1 | 1991 | 15 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 723 | 0.020 |
Why?
|
| Ear | 1 | 1991 | 25 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2011 | 121 | 0.020 |
Why?
|
| Auditory Perception | 1 | 1991 | 37 | 0.020 |
Why?
|
| Pregnancy | 1 | 2024 | 7174 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 422 | 0.020 |
Why?
|
| Pimozide | 1 | 1990 | 6 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 2 | 1987 | 8 | 0.020 |
Why?
|
| Neurocognitive Disorders | 1 | 1990 | 67 | 0.020 |
Why?
|
| Receptors, Dopamine | 2 | 1989 | 40 | 0.020 |
Why?
|
| Blood Pressure | 3 | 1999 | 1364 | 0.020 |
Why?
|
| Connecticut | 1 | 2009 | 20 | 0.020 |
Why?
|
| Violence | 1 | 1990 | 116 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1993 | 542 | 0.020 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 14 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 3153 | 0.020 |
Why?
|
| Government Programs | 1 | 2008 | 11 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 681 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 107 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 571 | 0.020 |
Why?
|
| Biophysics | 1 | 2008 | 50 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2008 | 63 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 133 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 474 | 0.020 |
Why?
|
| Likelihood Functions | 2 | 1999 | 114 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 1989 | 491 | 0.020 |
Why?
|
| Amino Acids | 3 | 1994 | 664 | 0.020 |
Why?
|
| Agonistic Behavior | 1 | 2006 | 8 | 0.020 |
Why?
|
| Arginine Vasopressin | 2 | 1999 | 28 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2007 | 84 | 0.020 |
Why?
|
| Pharynx | 1 | 2006 | 64 | 0.020 |
Why?
|
| Alprazolam | 1 | 1986 | 6 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1988 | 277 | 0.020 |
Why?
|
| Loneliness | 1 | 2006 | 24 | 0.020 |
Why?
|
| Entropy | 1 | 2006 | 26 | 0.020 |
Why?
|
| Globus Pallidus | 1 | 2006 | 64 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 256 | 0.020 |
Why?
|
| Enuresis | 1 | 1985 | 7 | 0.020 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1985 | 26 | 0.020 |
Why?
|
| Receptors, Adrenergic | 1 | 1985 | 29 | 0.020 |
Why?
|
| Hospitalization | 2 | 1995 | 1780 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 232 | 0.020 |
Why?
|
| Hyperphagia | 1 | 1985 | 44 | 0.020 |
Why?
|
| Seasons | 1 | 2006 | 310 | 0.010 |
Why?
|
| Movement | 1 | 2006 | 171 | 0.010 |
Why?
|
| Peptic Ulcer | 1 | 1985 | 148 | 0.010 |
Why?
|
| Migraine Disorders | 1 | 1985 | 63 | 0.010 |
Why?
|
| Public Health Administration | 1 | 2004 | 9 | 0.010 |
Why?
|
| Drug Approval | 1 | 2004 | 43 | 0.010 |
Why?
|
| Advisory Committees | 1 | 2004 | 153 | 0.010 |
Why?
|
| Parenting | 1 | 2007 | 331 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2003 | 110 | 0.010 |
Why?
|
| Nausea | 1 | 2003 | 86 | 0.010 |
Why?
|
| Growth Hormone | 3 | 1988 | 150 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 2002 | 8 | 0.010 |
Why?
|
| Pain | 1 | 1985 | 462 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 110 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 553 | 0.010 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2003 | 91 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 167 | 0.010 |
Why?
|
| Skull | 1 | 2002 | 142 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 332 | 0.010 |
Why?
|
| Arthritis | 1 | 2000 | 80 | 0.010 |
Why?
|
| Grooming | 1 | 1999 | 8 | 0.010 |
Why?
|
| Opioid Peptides | 1 | 1999 | 4 | 0.010 |
Why?
|
| Receptors, Neuropeptide | 1 | 1999 | 9 | 0.010 |
Why?
|
| Receptors, Vasopressin | 1 | 1999 | 11 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1999 | 245 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1999 | 185 | 0.010 |
Why?
|
| Stereotypic Movement Disorder | 1 | 1999 | 13 | 0.010 |
Why?
|
| Myocarditis | 1 | 2000 | 130 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1999 | 76 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 1999 | 139 | 0.010 |
Why?
|
| Somatostatin | 1 | 1999 | 71 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 1999 | 74 | 0.010 |
Why?
|
| Probability | 1 | 1999 | 320 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 815 | 0.010 |
Why?
|
| Acute Disease | 2 | 1992 | 1110 | 0.010 |
Why?
|
| Adolescent Psychiatry | 1 | 1997 | 15 | 0.010 |
Why?
|
| Child Psychiatry | 1 | 1997 | 16 | 0.010 |
Why?
|
| Streptococcus | 1 | 1997 | 61 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 1999 | 247 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 759 | 0.010 |
Why?
|
| Pituitary-Adrenal System | 1 | 1996 | 36 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1997 | 266 | 0.010 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1996 | 63 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1995 | 27 | 0.010 |
Why?
|
| Memory | 1 | 1999 | 361 | 0.010 |
Why?
|
| Tape Recording | 1 | 1995 | 3 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 710 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1994 | 43 | 0.010 |
Why?
|
| Neurophysins | 1 | 1994 | 4 | 0.010 |
Why?
|
| Psychiatric Department, Hospital | 1 | 1993 | 21 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1994 | 122 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 590 | 0.010 |
Why?
|
| Self Concept | 1 | 1994 | 155 | 0.010 |
Why?
|
| Aging | 1 | 1999 | 1183 | 0.010 |
Why?
|
| Hypothalamus | 1 | 1994 | 207 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 3676 | 0.010 |
Why?
|
| Pyrazines | 1 | 1992 | 75 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 1994 | 483 | 0.010 |
Why?
|
| Schizotypal Personality Disorder | 1 | 1990 | 7 | 0.010 |
Why?
|
| Patient Discharge | 1 | 1993 | 490 | 0.010 |
Why?
|
| Cocaine | 1 | 1989 | 207 | 0.000 |
Why?
|
| Influenza, Human | 1 | 1994 | 658 | 0.000 |
Why?
|
| Neurons | 1 | 1997 | 1922 | 0.000 |
Why?
|
| Diet | 1 | 1994 | 1138 | 0.000 |
Why?
|
| Cardiovascular System | 1 | 1987 | 106 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1987 | 851 | 0.000 |
Why?
|
| Infant | 1 | 1995 | 12477 | 0.000 |
Why?
|